Clinical Trial Update: A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial comparing telbivudine (LdT) with lamivudine in adults with compensated chronic hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Epivir-HBV (lamivudine)
• Telbivudine (telbivudine)

Snippet

Sponsor: Novartis | Conditions: Chronic Hepatitis B | Phase 3 | Status: COMPLETED